Lupin Pharma: Phase 3 Trial Of Single-Dose Solosec Met Primary Endpoint

Lupin Pharmaceuticals Inc. (LUPIN, 500257) on Monday announced positive top-line results from its pivotal Phase 3 clinical trial to assess the efficacy and safety of single-dose Solosec or secnidazole 2g oral granules in 147 female patients with trichomoniasis.

from RTT - Biotech https://ift.tt/3b3aUh5
via IFTTT